PharmTech News

Articles

Bristol Myers Squibb will handle the development and commercialization of DF6002 and its related products worldwide, including strategic decisions, regulatory responsibilities, funding, and manufacturing.

Bristol Myers Squibb and Dragonfly Therapeutics Form $475-Million Immunotherapy Deal

The deal is expected to close during the second half of 2020.

J&J to Acquire Momenta Pharmaceuticals for $6.5 billion

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

A new FDA guidance provides answers to questions about when the agency will seek to visit a site during the COVID-19 pandemic and how it will respond when a needed inspection cannot be conducted safely. 

FDA May Delay Approval of Drugs Where Necessary Inspection Is Not Feasible

The acquisition will give Sanofi access to Principia’s Bruton tyrosine kinase (BTK) inhibitors to add to its portfolio of next-generation transformative treatments for autoimmune diseases.

Sanofi to Acquire Principia Biopharma for $3.68 Billion

In combination with BARDA’s previous award, the commitment for early access to Moderna’s vaccine candidate has now reached to up to $2.48 billion.

US Government Awards Moderna $1.5 billion for COVID-19 Vaccine Candidate

The company will use the acquisition to further its drug development pipeline in women’s healthcare.

Bayer to Acquire KaNDy Therapeutics for up to $875 Million

Questions about safety and efficacy surround Putin’s announced approval of a COVID-19 vaccine, with no supporting clinical trial results.

Researchers Question Russia’s COVID-19 Vaccine Claim

Citing undisclosed allegations against Kodak, the DFC placed a hold on a potential $765 million loan to launch US-based API manufacturing.

Allegations Put Kodak Pharmaceuticals Loan on Hold

Sanofi and GlaxoSmithKline have been selected to supply the US government and the European Union with millions of doses of their COVID-19 vaccine candidate.

Sanofi and GSK to Supply COVID-19 Vaccine to US Government and European Union

The company is working to ensure broad global access to its COVID-19 vaccine candidate, following approval from regulators.

Top News